Clinical Trial Update: An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Open-label Phase II trial evaluating gefitinib (IRESSA) in patients with malignant mesothelioma has been completed. The study assessed the safety and potential …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED